GlassScriptPhysician profile
Seema Antony
NPI 1457914657
$1,793.75
in general payments reported to CMS, 2019-2025
19 companies · $461 in 2025
The $461 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $59.22 · 2022: $306 · 2023: $525 · 2024: $442 · 2025: $461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,401 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,401.36 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $287.83 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Abbvie INC. | $267.20 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $221.30 | 2022-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Teva Pharmaceuticals USA, INC. | $148.51 | 2022-2025 | Austedo Xr, Uzedy, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $139.30 | 2024-2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $102.68 | 2021-2024 | Caplyta |
| Lundbeck LLC | $100.94 | 2022-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $96.52 | 2023-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $75.18 | 2023-2025 | Auvelity |
| Corium, LLC | $73.88 | 2022-2025 | Azstarys |
| Indivior INC. | $57.51 | 2022-2023 | Perseris |
| Uswm, LLC | $48.32 | 2023 | Lucemyra, Zimhi |
| Almatica Pharma LLC | $40.48 | 2024-2025 | Loreev Xr |
| Janssen Pharmaceuticals, INC | $37.71 | 2023-2025 | Invega Sustenna |
| Takeda Pharmaceuticals U.S.A., INC. | $31.54 | 2024 | Trintellix |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $22.05 | 2022 | |
| Vanda Pharmaceuticals INC. | $15.99 | 2023 | Fanapt, Hetlioz |
| Supernus Pharmaceuticals, INC. | $14.50 | 2025 | Qelbree |
| Sunovion Pharmaceuticals INC. | $12.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seema Antony listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.